Get started
Author

Giulia Rizzuto

Observed names: G Rizzuto, G. Rizzuto, Rizzuto Giulia, Rizzuto, Giulia
OpenAlex ID: A5081551616
The PROSIT-BIO Cohort
2017 · Gionata Fiorino, Natalia Manetti, et al. · Inflammatory Bowel Diseases · 132
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy
2018 · Alessandro Armuzzi, Gionata Fiorino, et al. · Inflammatory Bowel Diseases · 58
PDF
Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: Early and long-term data from a retrospective observational study
2012 · Filippo Mocciaro, Sara Renna, et al. · Journal of Crohn s and Colitis · 57
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches
2020 · Fabio Salvatore Macaluso, Walter Fries, et al. · Inflammatory Bowel Diseases · 49
The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases
2018 · Fabio Salvatore Macaluso, Rosalba Orlando, et al. · Digestive and Liver Disease · 45
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease
2022 · Laurent Peyrin-Biroulet, Jean-François Rahier, et al. · Clinical Gastroenterology and Hepatology · 42
PDF
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn’s Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease
2018 · Fabio Salvatore Macaluso, Walter Fries, et al. · Journal of Crohn s and Colitis · 36
Effectiveness and safety of vedolizumab in biologically naïve patients: A real‐world multi‐centre study
2020 · Fabio Salvatore Macaluso, Walter Fries, et al. · United European Gastroenterology Journal · 34
PDF
Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience
2017 · Fabio Salvatore Macaluso, Sara Renna, et al. · Scandinavian Journal of Gastroenterology · 27
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis
2020 · Fabio Salvatore Macaluso, Marco Ventimiglia, et al. · Digestive and Liver Disease · 25
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501
2021 · Fabio Salvatore Macaluso, Maria Cappello, et al. · Journal of Gastroenterology and Hepatology · 23
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease
2020 · Fabio Salvatore Macaluso, Marco Ventimiglia, et al. · Journal of Gastroenterology and Hepatology · 23
PDF
The Addition of an Immunosuppressant After Loss of Response to Anti-TNFα Monotherapy in Inflammatory Bowel Disease: A 2-Year Study
2018 · Fabio Salvatore Macaluso, Chiara Sapienza, et al. · Inflammatory Bowel Diseases · 20
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19
2022 · Fabio Salvatore Macaluso, Alessandra Giuliano, et al. · Inflammatory Bowel Diseases · 19
The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study
2022 · Aurelien Amiot, Jean-Francois Rahier, et al. · Journal of Crohn s and Colitis · 18
PDF
P387 The addition of an immunosuppressant is an effective optimization strategy after loss of response to anti-TNF-alpha monotherapy in patients with inflammatory bowel disease: a two-year experience
2017 · F.S. Macaluso, C. Sapienza, et al. · Journal of Crohn s and Colitis · 18
Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
2022 · Fabio Salvatore Macaluso, Mariabeatrice Principi, et al. · Digestive and Liver Disease · 12
PDF
Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis
2016 · S. Renna, E. Orlando, et al. · Alimentary Pharmacology & Therapeutics · 10
PDF
Selective Use of Combination Therapy in Patients With Infliximab-resistant Inflammatory Bowel Disease: Data From a Tertiary Referral Center
2015 · Ambrogio Orlando, Sara Renna, et al. · Clinical Gastroenterology and Hepatology · 10
PDF
Letter: SPOSIB SB2—a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2
2018 · Fabio Salvatore Macaluso, Maria Cappello, et al. · Alimentary Pharmacology & Therapeutics · 9
PDF
Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants
2016 · Fabio Salvatore Macaluso, Marcello Maida, et al. · Digestive and Liver Disease · 9
Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD)
2024 · Gaetano Bergamaschi, Fabiana Castiglione, et al. · Digestive and Liver Disease · 7
PDF
Blood-based prognostic biomarkers in Crohn’s Disease patients on biologics: a promising tool to predict endoscopic outcomes
2021 · Federica Crispino, Mauro Grova, et al. · Expert Opinion on Biological Therapy · 7
Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study
2016 · Ambrogio Orlando, Sara Renna, et al. · Digestive and Liver Disease · 6
PDF
439 The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilars
2016 · Gionata Fiorino, Natalia Manetti, et al. · Gastroenterology · 6
Works count: 72
Citation count: 737
H-index: 16
I10-index: 19
Year
Topic
Type